An article published by Nature’s Science-Business Exchange validates Sibelius’ activity based approach to  compound discovery. The article entitled “Phenotypic Screening Take Two” discusses how Phenotypic screening is making a comeback as researchers as well as pharmaceutical companies have realised that reductionist approaches such as target-based screening are useful but maybe limiting.